Published Date : Jul 03, 2017
ALBANY, New York, July 3, 2017 - MarketResearchReports.biz has added a new report to its repository, titled, “MediPoint: Viscosupplementation - North America Analysis and Market Forecasts.” It throws light on the viscosupplementation products’ market in North America by analyzing the growth drivers and restraints and gauging its prospects in the years to come.
The report examines what clinical factors and technological specifications influence physicians in North America viscosupplementation market to choose one type of device over another. It further gathers inputs from physicians to understand the outlook for the market.
Viscosupplementation is a minimally invasive procedure which entails injecting gel-like substances into a joint to help improve the viscous properties of synovial fluid. Currently, only hyaluronate injections are the approved viscosupplementation treatment of osteoarthritis of the knee.
North America is a leading market of viscosupplementation globally on account of a robust demand. This is because of a growing pool of elderly, the alarming increase in obese population, increasing awareness among patients about latest drugs and devices to treat osteoarthritis, demand for minimally invasive products, and ability of people to spend on high priced products. Other factors serving to stoke growth in the market is the superior research and development infrastructure in the region which is resulting in product and process development.
For Sample Copy, click here: https://www.marketresearchreports.biz/sample/sample/1177529
The report studies in-depth the three key regions in the North America viscosupplementation market – Canada, Mexico, and the U.S. It presents information on their revenues, sizes, shares, and possible growth trajectory in the upcoming years.
Some of the hyaluronates that have been approved by the FDA and are currently purveyed in the North America viscosupplementation market are Orthovisc (Anika Therapeutics), Hyalgan (Sanofi), Supartz and Gel-One (Seikagaku Corporation), Euflexxa (Ferring Pharmaceuticals, Inc.), Durolane (Q MED AB), and Synvisc One (Genzyme).
The report discusses recent events, such as latest product launches, pipeline products, and technological developments, serving to reshape the contours of the North America viscosupplementation market. It segments the market based on the type of devices and procedure trends and studies each segment in details. It also finds the top-selling products in each segment. Other things highlighted in the report are the pricing trends and revenue trends.
The report also furnishes a thorough peek into the current competitive dynamics in the North America viscosupplementation market. It draws up a list of some of the major players in the market, namely Anika Therapeutics, Fidia Farmaceutici, Sanofi, Ferring Pharmaceuticals, and Seikagaku Corporation. It examines their product portfolios in details and also presents their sales and revenue figures, market shares, and future growth prospects. It furnishes valuable information on the opportunities and threats awaiting them in the foreseeable future so as to empower them to frame winning sales and marketing strategies and avoid potential pitfalls.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com